Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

March 30, 2024

Study Completion Date

December 31, 2025

Conditions
Critical IllnessDeliriumCognitive Impairment
Interventions
DRUG

Guanfacine

Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.

DRUG

Placebo

Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.

Trial Locations (1)

37212

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

National Institute on Aging (NIA)

NIH

lead

Vanderbilt University Medical Center

OTHER